Literature DB >> 23202869

[Management of anaphylaxis : part 2: treatment and emergency equipment].

L Klimek1, U Goebel, A Glowania.   

Abstract

Anaphylaxis is an extreme form of allergic reaction that can be life-threatening. Early treatment of circulatory and pulmonary disturbances is decisive for prognosis. Initial management of anaphylaxis comprises, where possible, interrupting allergen exposure; ensuring a stable airway; summoning emergency services; placing the patient in a safe position, obtaining venous access and monitoring vital signs. Adrenaline, histamine-antagonists and glucocorticoids have proven effective, as has administration of oxygen and volume substitutes. Many anaphylaxis patients are unable to successfully avoid the elicitor and the feasibility of self-treatment is limited if the patient is inadequately informed. An educational program for adult patients and parents of children with a high risk of anaphylaxis has been developed by the German Working Group for Anaphylaxis Training and Education (AGATE). This program aims to help prevent anaphylactic attacks, foster optimal first-line treatment and offer psychological and social support for anaphylaxis patients. Preliminary results confirm the efficacy of the AGATE approach. This article presents an overview of the stage-wise management of anaphylaxis in accordance with the S2 position paper of the German allergological societies and international guidelines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23202869     DOI: 10.1007/s00106-012-2588-9

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  12 in total

Review 1.  Lessons for management of anaphylaxis from a study of fatal reactions.

Authors:  R S Pumphrey
Journal:  Clin Exp Allergy       Date:  2000-08       Impact factor: 5.018

Review 2.  Adrenaline in the treatment of anaphylaxis: what is the evidence?

Authors:  Andrew P C McLean-Tooke; Claire A Bethune; Ann C Fay; Gavin P Spickett
Journal:  BMJ       Date:  2003-12-06

3.  Reducing the risk of anaphylaxis during anaesthesia: guidelines for clinical practice.

Authors:  P M Mertes; M C Laxenaire; A Lienhart; W Aberer; J Ring; W J Pichler; P Demoly
Journal:  J Investig Allergol Clin Immunol       Date:  2005       Impact factor: 4.333

Review 4.  Therapeutic controversies in the management of acute anaphylaxis.

Authors:  A F Brown
Journal:  J Accid Emerg Med       Date:  1998-03

Review 5.  Guidelines for the management of anaphylaxis in the emergency department.

Authors:  M Gavalas; A Sadana; S Metcalf
Journal:  J Accid Emerg Med       Date:  1998-03

Review 6.  Epidemiology of life-threatening and lethal anaphylaxis: a review.

Authors:  D A Moneret-Vautrin; M Morisset; J Flabbee; E Beaudouin; G Kanny
Journal:  Allergy       Date:  2005-04       Impact factor: 13.146

7.  A comparison of 4 epinephrine autoinjector delivery systems: usability and patient preference.

Authors:  Stephanie Guerlain; Akilah Hugine; Lu Wang
Journal:  Ann Allergy Asthma Immunol       Date:  2010-02       Impact factor: 6.347

8.  Reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice.

Authors:  P M Mertes; J M Malinovsky; L Jouffroy; W Aberer; I Terreehorst; K Brockow; P Demoly
Journal:  J Investig Allergol Clin Immunol       Date:  2011       Impact factor: 4.333

9.  World Allergy Organization anaphylaxis guidelines: summary.

Authors:  F Estelle R Simons; Ledit R F Ardusso; M Beatrice Bilò; Yehia M El-Gamal; Dennis K Ledford; Johannes Ring; Mario Sanchez-Borges; Gian Enrico Senna; Aziz Sheikh; Bernard Y Thong
Journal:  J Allergy Clin Immunol       Date:  2011-03       Impact factor: 10.793

10.  Proposed use of adrenaline (epinephrine) in anaphylaxis and related conditions: a study of senior house officers starting accident and emergency posts.

Authors:  L L Gompels; C Bethune; S L Johnston; M M Gompels
Journal:  Postgrad Med J       Date:  2002-07       Impact factor: 2.401

View more
  2 in total

1.  [Immunotherapy of allergic rhinitis without allergens? : new options for immunomodulation by vaccination with virus-like particles and CpG motifs].

Authors:  L Klimek; J Willers; P Schendzielorz; T M Kündig; G Senti
Journal:  HNO       Date:  2013-10       Impact factor: 1.284

2.  [ASA-intolerance syndrome and persistent rhinosinusitis : Differential diagnosis and treatment].

Authors:  H Kirsche; L Klimek
Journal:  HNO       Date:  2015-05       Impact factor: 1.284

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.